Phase IIb Clinical Study to Assess the Efficacy and Safety of GenSci120 Injection in Patients With Moderately to Severely Active RA Who Have an Inadequate Response to at Least One DMARD

NCT07423533 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

450

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

DRUG: GenSci120 150 mg
DRUG: GenSci120 600 mg
DRUG: GenSci120 1000 mg
DRUG: adalimumab injection 40 mg
DRUG: Placebo

Sponsor

Changchun GeneScience Pharmaceutical Co., Ltd.